Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Apheresis System with Secondary Devices Evaluated

By LabMedica International staff writers
Posted on 06 Jun 2017
Therapeutic plasma exchange (TPE) reduces the levels of pathological factors circulating in the patient’s plasma and it relieves symptoms or prevents further destruction of the involved organ or system.

As an alternative to TPE, specific plasma purification methods such as lipoprotein apheresis or immunoadsorption have been developed for selective removal of the purported pathological substances from the separated plasma.

Scientists at the University Hospital Jena (Germany) examined the last 300 data log files from November 2015 until October 2016. More...
Of these 300 procedures, 149 secondary plasma treatments were conducted in 13 patients, 76 immunoadsorption (IA) and 73 lipoprotein apheresis (LA). Nine patients had IA due to transplantation and autoimmune diseases. Four patients were treated with LA after heart transplantation. Of the procedures, 62% were performed using peripheral venous access, even in patients with a low inlet blood flow.

All patients were treated with the Spectra Optia Apheresis System. An adsorption matrix, Immunosorba, was used for IA, and the Fresenius Medical Care Monet or Evaflux was used for LA. The immunoadsorption (IA) columns need an additional device for secondary plasma processing. Adasorb devices allow adsorption and desorption (regeneration) of the columns. In one session, the device treats up to 10,000 mL of plasma.

A central catheter was required only in 15% cases, and an arteriovenous fistula in 23% of the procedures. Anticoagulation management differed in both procedures. The LA procedures required a higher amount of citrate as they were performed using only citrate. The IA procedures required less citrate because a mixture of citrate and heparin was used. The scientists did not observe clotting or bleeding, regardless of heparin use. Due to strict calcium management, no patient showed signs of hypocalcemia. They found that the targeted substances could be reduced significantly: lipoprotein (a) (Lpa) level by 68%, low-density lipoprotein-cholesterol by 57%, and immunoglobulin G (IgG) from 6.6 to 2.61 g/L.

The authors concluded that the Spectra Optia had a high plasma extraction efficiency, which allows secondary plasma device procedures with peripheral venous access and moderate inlet flow rates. One of the biggest advantages of the Optia is its high plasma removal efficiency. Ideal plasma flow rates for filter or IA columns could be reached faster. The study was published on May 24, 2017, in the International Journal of Clinical Transfusion Medicine.

Related Links
University Hospital Jena


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
Electrolyte Analyzer
BKE-B
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Roche’s CE-Marked Elecsys pTau217 blood test is a single‑assay blood test measures phosphorylated tau 217, an indicator of amyloid pathology and a hallmark of Alzheimer’s disease (image credit: Shutterstock)

Blood-Based Alzheimer’s Test Gains CE Mark for Amyloid Pathology Detection

Alzheimer’s disease is the most common cause of dementia, yet confirmatory testing remains invasive and hard to access. Diagnosis currently takes an average of 3.5 years, and about 75% of people with dementia... Read more

Molecular Diagnostics

view channel
Image: Clarifying tumor microenvironment features and cancer-cell programs linked to treatment response could provide earlier insight into triple-negative breast cancer therapy (image credit: Shutterstock)

Gene Panel Shows Promise for Predicting Chemotherapy Response in TNBC

Triple-negative breast cancer (TNBC) is an aggressive subtype commonly treated with chemotherapy, yet outcomes vary widely among patients. Understanding the tumor features that drive this variability remains... Read more

Microbiology

view channel
Image: The initiative combines epidemiological and microbiological data with whole-genome sequencing to characterize circulating hospital lineages and resistance determinants (image credit: Shutterstock)

Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals

Antimicrobial resistance (AMR) poses a growing threat to patient safety, with carbapenem-resistant Enterobacterales causing difficult-to-treat infections and leaving clinicians with limited therapeutic options.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.